Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

Helvia. Repositorio Institucional de la Universidad de Córdoba
Publication Artículo científico (JournalArticle)

Effects of EHP-101 on inflammation and remyelination in murine models of Multiple sclerosis

  • Navarrete, Carmen
  • García-Martín, Adela
  • Garrido Rodríguez-Córdoba, Martín
  • Mestre, Leyre
  • Feliú, Ana
  • Guaza, Carmen
  • Calzado Canale, Marco Antonio
  • Muñoz, Eduardo
Multiple Sclerosis (MS) is characterized by a combination of inflammatory and neurodegenerative processes in the spinal cord and the brain. Natural and synthetic cannabinoids such as VCE-004.8 have been studied in preclinical models of MS and represent promising candidates for drug development. VCE-004.8 is a multitarget synthetic cannabidiol (CBD) derivative acting as a dual Peroxisome proliferator-activated receptor-gamma/Cannabinoid receptor type 2 (PPARγ/CB2) ligand agonist that also activates the Hypoxia-inducible factor (HIF) pathway. EHP-101 is an oral lipidic formulation of VCE-004.8 that has shown efficacy in several preclinical models of autoimmune, inflammatory, fibrotic, and neurodegenerative diseases. EHP-101 alleviated clinical symptomatology in EAE and transcriptomic analysis demonstrated that EHP-101 prevented the expression of many inflammatory genes closely associated with MS pathophysiology in the spinal cord. EHP-101 normalized the expression of several genes associated with oligodendrocyte function such as Teneurin 4 (Tenm4) and Gap junction gamma-3 (Gjc3) that were downregulated in EAE. EHP-101 treatment prevented microglia activation and demyelination in both the spinal cord and the brain. Moreover, EAE was associated with a loss in the expression of Oligodendrocyte transcription factor 2 (Olig2) in the corpus callosum, a marker for oligodendrocyte differentiation, which was restored by EHP-101 treatment. In addition, EHP-101 enhanced the expression of glutathione S-transferase pi (GSTpi), a marker for mature oligodendrocytes in the brain. We also found that a diet containing 0.2% cuprizone for six weeks induced a clear loss of myelin in the brain measured by Cryomyelin staining and Myelin basic protein (MBP) expression. Moreover, EHP-101 also prevented cuprizone-induced microglial activation, astrogliosis and reduced axonal damage. Our results provide evidence that EHP-101 showed potent anti-inflammatory activity, prevented demyelination, and enhanced remyelination. Therefore, EHP-101 represents a promising drug candidate for the potential treatment of different forms of MS.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The endocannabinoid 2-AG enhances spontaneous remyelination by targeting microglia

  • Mecha, Miriam
  • Yanguas-Casás, Natalia
  • Feliú, Ana
  • Mestre, Leyre
  • Carrillo-Salinas, F. J.
  • Azcoitia, I.
  • Yong, Y. W.
  • Guaza, Carmen
Remyelination is an endogenous process by which functional recovery of damaged neurons is achieved by reinstating the myelin sheath around axons. Remyelination has been documented in multiple sclerosis (MS) lesions and experimental models, although it is often incomplete or fails to affect the integrity of the axon, thereby leading to progressive disability. Microglia play a crucial role in the clearance of the myelin debris produced by demyelination and in inflammation-dependent OPC activation, two processes necessary for remyelination to occur. We show here that following corpus callosum demyelination in the TMEV-IDD viral murine model of MS, there is spontaneous and partial remyelination that involves a temporal discordance between OPC mobilization and microglia activation. Pharmacological treatment with the endocannabinoid 2-AG enhances the clearance of myelin debris by microglia and OPC differentiation, resulting in complete remyelination and a thickening of the myelin sheath. These results highlight the importance of targeting microglia during the repair processes in order to enhance remyelination., This work was supported by grants from the Ministerio de Economía y Competitividad (MINECO SAF2013-42784-R, SAF2016 76449-R), and the Red Española de Esclerosis Múltiple (REEM: RD12/0032/0008, RD16/0015/0021) sponsored by the Fondo de Investigación Sanitaria (FIS)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Gut microbiota, cannabinoid system and neuroimmune interactions: New perspectives in multiple sclerosis

  • Mestre, Leyre
  • Carrillo-Salinas, F. J.
  • Mecha, Miriam
  • Feliú, Ana
  • Guaza, Carmen
The gut microbiota plays a fundamental role on the education and function of the host immune system. Immunological dysregulation is the cause of numerous human disorders such as autoimmune diseases and metabolic disorders frequently associated with inflammatory processes therefore is critical to explore novel mechanisms involved in maintaining the immune system homeostasis. The cannabinoid system and related bioactive lipids participate in multiple central and peripheral physiological processes that affect metabolic, gastrointestinal and neuroimmune regulatory mechanisms displaying a modulatory role and contributing to the maintenance of the organism’s homeostasis. In this review, we gather the knowledge on the gut microbiota-endocannabinoids interactions and their impact on autoimmune disorders such as inflammatory bowel disease, rheumatoid arthritis and particularly, multiple sclerosis (MS) as the best example of a CNS autoimmune disorder. Furthermore, we contribute to this field with new data on changes in many elements of the cannabinoid system in a viral model of MS after gut microbiota manipulation by both antibiotics and probiotics. Finally, we highlight new therapeutic opportunities, under an integrative view, targeting the eCBS and the commensal microbiota in the context of neuroinflammation and MS., The authors gratefully acknowledge support from the Spanish Network of Multiple Sclerosis Research, REEM, RD16/0015/0021 sponsored by the Fondo de Investigación Sanitaria (FIS) and SAF2016-76449-R from Ministry of the Economy and Competitiveness (MINECO, Spain)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

2‐AG limits Theiler's virus induced acute neuroinflammation by modulating microglia and promoting MDSCs

  • Mecha, Miriam
  • Feliú, Ana
  • Machín-Díaz, Isabel
  • Cordero, César
  • Carrillo-Salinas, F. J.
  • Mestre, Leyre
  • Hernández-Torres, Gloria
  • López-Rodríguez, María L.
  • Castro Soubriet, Fernando de
  • Clemente, Diego
  • Guaza, Carmen
The innate immune response is mediated by primary immune modulators such as cytokines and chemokines that together with immune cells and resident glia orchestrate CNS immunity and inflammation. Growing evidence supports that the endocannabinoid 2‐arachidonoylglycerol (2‐AG) exerts protective actions in CNS injury models. Here, we used the acute phase of Theiler's virus induced demyelination disease (TMEV‐IDD) as a model of acute neuroinflammation to investigate whether 2‐AG modifies the brain innate immune responses to TMEV and CNS leukocyte trafficking. 2‐AG or the inhibition of its hydrolysis diminished the reactivity and number of microglia at the TMEV injection site reducing their morphological complexity and modulating them towards an anti‐inflammatory state via CB2 receptors. Indeed, 2‐AG dampened the infiltration of immune cells into the CNS and inhibited their egress from the spleen, resulting in long‐term beneficial effects at the chronic phase of the disease. Intriguingly, it is not a generalized action over leukocytes since 2‐AG increased the presence and suppressive potency of myeloid derived suppressor cells (MDSCs) in the brain resulting in higher apoptotic CD4+ T cells at the injection site. Together, these data suggest a robust modulatory effect in the peripheral and central immunity by 2‐AG and highlight the interest of modulating endogenous cannabinoids to regulate CNS inflammatory conditions., This work was supported by grants to CG, DC and MLR from Ministry of the Economy and Competitiveness (CG: MINECO SAF2013–42784‐R, SAF2016 76449‐R; MLR: SAF2013–48271, DC: PI15/00963), the Comunidad de Madrid (CG: S2010/BMD‐2308 and MLR: S2010/BMD‐2353), the Red Española de Esclerosis Múltiple (CG: REEM: RD12/0032/0008; RD16/0015/0021; FC: RD12/0032/12, DC: RD16/0015/0019) sponsored by the Fondo de Investigación Sanitaria (FIS), partially financed by F.E.D.E.R.; European Union “Una manera de hacer Europa” and ARSEP Foundation to DC. Diego Clemente's group was sponsored by ADEM‐TO, Aciturri Aeronáutica S.L. and Vesuvius Ibérica LA. M.M. is a senior postdoctoral supported by the Comunidad de Madrid (S2010/BMD‐2308) and hired by MINECO; DC and IM‐D are hired by SESCAM., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy

  • Navarrete, Carmen
  • Carrillo-Salinas, F. J.
  • Palomares, Belén
  • Mecha, Miriam
  • Jiménez-Jiménez, Carla
  • Mestre, Leyre
  • Feliú, Ana
  • Bellido, María Luz
  • Fiebich, Bernd L.
  • Appendino, Giovanni
  • Calzado, Marco A.
[Background] Multiple sclerosis (MS) is characterized by a combination of inflammatory and neurodegenerative processes variously dominant in different stages of the disease. Thus, immunosuppression is the goal standard for the inflammatory stage, and novel remyelination therapies are pursued to restore lost function. Cannabinoids such as 9Δ-THC and CBD are multi-target compounds already introduced in the clinical practice for multiple sclerosis (MS). Semisynthetic cannabinoids are designed to improve bioactivities and druggability of their natural precursors. VCE-004.8, an aminoquinone derivative of cannabidiol (CBD), is a dual PPARγ and CB2 agonist with potent anti-inflammatory activity. Activation of the hypoxia-inducible factor (HIF) can have a beneficial role in MS by modulating the immune response and favoring neuroprotection and axonal regeneration., [Methods] We investigated the effects of VCE-004.8 on the HIF pathway in different cell types. The effect of VCE-004.8 on macrophage polarization and arginase 1 expression was analyzed in RAW264.7 and BV2 cells. COX-2 expression and PGE2 synthesis induced by lipopolysaccharide (LPS) was studied in primary microglia cultures. The efficacy of VCE-004.8 in vivo was evaluated in two murine models of MS such as experimental autoimmune encephalomyelitis (EAE) and Theiler’s virus-induced encephalopathy (TMEV)., [Results] Herein, we provide evidence that VCE-004.8 stabilizes HIF-1α and HIF-2α and activates the HIF pathway in human microvascular endothelial cells, oligodendrocytes, and microglia cells. The stabilization of HIF-1α is produced by the inhibition of the prolyl-4-hydrolase activity of PHD1 and PDH2. VCE-004.8 upregulates the expression of HIF-dependent genes such as erythropoietin and VEGFA, induces angiogenesis, and enhances migration of oligodendrocytes. Moreover, VCE-004.8 blunts IL-17-induced M1 polarization, inhibits LPS-induced COX-2 expression and PGE2 synthesis, and induces expression of arginase 1 in macrophages and microglia. In vivo experiments showed efficacy of VCE-004.8 in EAE and TMEV. Histopathological analysis revealed that VCE-004.8 treatments prevented demyelination, axonal damage, and immune cells infiltration. In addition, VCE-004.8 downregulated the expression of several genes closely associated with MS physiopathology, including those underlying the production of chemokines, cytokines, and adhesion molecules., [Conclusions] This study provides new significant insights about the potential role of VCE-004.8 for MS treatment by ameliorating neuroinflammation and demyelination., This work was supported by grants SAF2014-53763-P (EM), SAF2017-87701-R (EM), and SAF2016-76449-R (GC) from the Ministry of the Economy and Competition (MINECO) co-financed with the European Union FEDER funds. GC was also supported by the Red Española de Esclerosis Múltiple (REEM: RD16/0015/0021) sponsored by the Fondo de Investigación Sanitaria (FIS); MAC was supported by the Instituto de Salud Carlos III (PIE14/00005) co-funded by the European Regional Development Fund/European Social Fund “Investing in your future”., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

2-Arachidonoylglycerol Reduces Proteoglycans and Enhances Remyelination in a Progressive Model of Demyelination

  • Feliú, Ana
  • Bonilla del Río, Itziar
  • Carrillo-Salinas, F. J.
  • Hernández-Torres, Gloria
  • Puente, Nagore
  • Ortega-Gutiérrez, S.
  • López-Rodríguez, María L.
  • Grandes, Pedro
  • Mecha, Miriam
  • Guaza, Carmen
The failure to undergo remyelination is a critical impediment to recovery in multiple sclerosis. Chondroitin sulfate proteoglycans (CSPGs) accumulate at demyelinating lesions creating a nonpermissive environment that impairs axon regeneration and remyelination. Here, we reveal a new role for 2-arachidonoylglycerol (2-AG), the major CNS endocannabinoid, in the modulation of CSPGs deposition in a progressive model of multiple sclerosis, the Theiler's murine encephalomyelitis virus-induced demyelinating disease. Treatment with a potent reversible inhibitor of the enzyme monoacylglycerol lipase, which accounts for 85% of the 2-AG degradation in the mouse CNS, modulates neuroinflammation and reduces CSPGs accumulation and astrogliosis around demyelinated lesions in the spinal cord of Theiler's murine encephalomyelitis virus-infected mice. Inhibition of 2-AG hydrolysis augments the number of mature oligodendrocytes and increases MBP, leading to remyelination and functional recovery of mice. Our findings establish a mechanism for 2-AG promotion of remyelination with implications in axonal repair in CNS demyelinating pathologies., This work was supported by Ministry of the Economy and Competition (MINECO) Grants SAF2013-42784-R and SAF2016-76449-R, Comunidad de Madrid Grant S2011/BMD-2308, and Red Española de Esclerosis Múltiple Grants RD12/0032/0008 and RD16/0015/0021 (sponsored by the Fondo de Investigación Sanitaria) to C.G., Basque Government Grant IT764-13, MINECO/FEDER Grant SAF2015-65034-R, and University of the Basque Country Grant UPV/EHU UFI11/41 to P.G., and MINECO Grant SAF2013-48271-C2-1-R to M.L.-R. None of the funding bodies played any role in the study design, data collection and analysis, the decision to publish, or the preparation of the manuscript. A.F. is a predoctoral fellow supported by MINECO Grant BES-2014-068459. We thank Laura Ramos for excellent technical support., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Involvement of Wnt7a in the role of M2c microglia in neural stem cell oligodendrogenesis

  • Mecha, Miriam
  • Yanguas-Casás, Natalia
  • Feliú, Ana
  • Mestre, Leyre
  • Carrillo-Salinas, F. J.
  • Riecken, Kristoffer
  • Gómez-Nicola, Diego
  • Guaza, Carmen
© The Author(s)., [Background]: The participation of microglia in CNS development and homeostasis indicate that these cells are pivotal for the regeneration that occurs after demyelination. The clearance of myelin debris and the inflammatory-dependent activation of local oligodendrocyte progenitor cells in a demyelinated lesion is dependent on the activation of M2c microglia, which display both phagocytic and healing functions. Emerging interest has been raised about the role of Wnt/β-catenin signaling in oligodendrogenesis and myelination. Besides, cytokines and growth factors released by microglia can control the survival, proliferation, migration, and differentiation of neural stem cells (NSCs), contributing to remyelination through the oligodendrocyte specification of this adult neurogenic niche., [Methods]:TMEV-IDD model was used to study the contribution of dorsal SVZ stem cells to newly born oligodendrocytes in the corpus callosum following demyelination by (i) en-face dorsal SVZ preparations; (ii) immunohistochemistry; and (iii) cellular tracking. By RT-PCR, we analyzed the expression of Wnt proteins in demyelinated and remyelinating corpus callosum. Using in vitro approaches with microglia cultures and embryonic NSCs, we studied the role of purified myelin, Wnt proteins, and polarized microglia-conditioned medium to NSC proliferation and differentiation. One-way ANOVA followed by Bonferroni’s post-hoc test, or a Student’s t test were used to establish statistical significance., [Results]: The demyelination caused by TMEV infection is paralleled by an increase in B1 cells and pinwheels in the dorsal SVZ, resulting in the mobilization of SVZ proliferative progenitors and their differentiation into mature oligodendrocytes. Demyelination decreased the gene expression of Wnt5a and Wnt7a, which was restored during remyelination. In vitro approaches show that Wnt3a enhances NSC proliferation, while Wnt7a and myelin debris promotes oligodendrogenesis from NSCs. As phagocytic M2c microglia secrete Wnt 7a, their conditioned media was found to induce Wnt/β-Catenin signaling in NSCs promoting an oligodendroglial fate., [Conclusions]: We define here the contribution of microglia to Wnt production depending on their activation state, with M1 microglia secreting the Wnt5a protein and M2c microglia secreting Wnt7a. Collectively, our data reveal the role of reparative microglia in NSC oligodendrogenesis with the involvement of Wnt7a., This work was supported by grants from the Ministerio de Economía y Competitividad (MINECO SAF2016 76449-R) and the Red Española de Esclerosis Múltiple (REEM: RD16/0015/0021), sponsored by the Fondo de Investigación Sanitaria (FIS)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Manipulation of Gut Microbiota Influences Immune Responses, Axon Preservation, and Motor Disability in a Model of Progressive Multiple Sclerosis

  • Mestre, Leyre
  • Carrillo-Salinas, F. J.
  • Mecha, Miriam
  • Feliú, Ana
  • Espejo, Carmen
  • Álvarez-Cermeño, José Carlos
  • Villar, Luisa María
  • Guaza, Carmen
Gut microbiota dysbiosis has been implicated in MS and other immune diseases, although it remains unclear how manipulating the gut microbiota may affect the disease course. Using a well-established model of progressive MS triggered by intracranial infection with Theiler's murine encephalomyelitis virus (TMEV), we sought to determine whether dysbiosis induced by oral antibiotics (ABX) administered on pre-symptomatic and symptomatic phases of the disease influences its course. We also addressed the effects of microbiota recolonization after ABX withdrawn in the presence or absence of probiotics. Central and peripheral immunity, plasma acetate and butyrate levels, axon damage and motor disability were evaluated. The cocktail of ABX prevented motor dysfunction and limited axon damage in mice, which had fewer CD4+ and CD8+ T cells in the CNS, while gut microbiota recolonization worsened motor function and axonal integrity. The underlying mechanisms of ABX protective effects seem to involve CD4+CD39+ T cells and CD5+CD1d+ B cells into the CNS. In addition, microglia adopted a round amoeboid morphology associated to an anti-inflammatory gene profile in the spinal cord of TMEV mice administered ABX. The immune changes in the spleen and mesenteric lymph nodes were modest, yet ABX treatment of mice limited IL-17 production ex vivo. Collectively, our results provide evidence of the functional relevance of gut microbiota manipulation on the neurodegenerative state and disease severity in a model of progressive MS and reinforce the role of gut microbiota as target for MS treatment., This work was supported by grants from the Ministerio de Economía y Competitividad (MINNECO SAF2016-76449-R) and the Red Española de Esclerosis Múltiple (REEM: RD16/0015/0021), sponsored by the Fondo de Investigación Sanitaria (FIS).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Otros (Other)

Experimental in vivo models for drug discovery in multiple sclerosis

  • Mestre, Leyre
  • Guaza, Carmen
Multiple sclerosis (MS) is the most common chronic demyelinating inflammatory disease of the central nervous system (CNS). Although it is a pathology only described in humans, there are several well-established animal models that are postulated as fundamental tools not only for elucidating the origin of the pathology (unknown to date), but also to develop new therapeutic drugs to slow down the disease progression. The main models of MS are classified according to the hypothetical origin of the pathology in “immune-mediated”, “virus-induced” and “toxin-induced” models. The experimental autoimmune encephalomyelitis (EAE) is the best characterized immune-mediated model to explore different aspects of autoimmunity in MS pathology. Regarding the virus-induced model, Theiler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD) allows not only the study of a large part of the histopathological and clinical signs, but also takes into account the hypothesis that viral infections would trigger an autoimmune disease. Toxin-induced models such as ethidium bromide, lysolecithin or cuprizone are useful for the evaluation of demyelination/remyelination processes. Throughout this chapter we will address the above experimental models from the perspective of the etiopathogenesis of MS and for the development of new potential therapeutic drugs., The authors gratefully acknowledge support from the Spanish Network of Multiple Sclerosis Research, REEM, RD16/0015/0021 sponsored by the Fondo de Investigación Sanitaria (FIS) and SAF2016-76449-R from Ministry of the Economy and Competitiveness (MINECO, Spain).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

2-arachidonoylglycerol reduces chondroitin sulphate proteoglycan production by astrocytes and enhances oligodendrocytes differentiation under inhibitory conditions

  • Feliú, Ana
  • Mestre, Leyre
  • Carrillo-Salinas, F. J.
  • Yong, V Wee
  • Mecha, Miriam
  • Guaza, Carmen
The failure to remyelinate and regenerate is a critical impediment to recovery in multiple sclerosis (MS), resulting in severe dysfunction and disability. The chondroitin sulfate proteoglycans (CSPGs) that accumulate in MS lesions are thought to be linked to the failure to regenerate, impeding oligodendrocyte precursor cell (OPC) differentiation and neuronal growth. The potential of endocannabinoids to influence MS progression may reflect their capacity to enhance repair processes. Here, we investigated how 2-arachidonoylglycerol (2-AG) may affect the production of the CSPGs neurocan and brevican by astrocytes in culture. In addition, we studied whether 2-AG promotes oligodendrocyte differentiation under inhibitory conditions in vitro. Following treatment with 2-AG or by enhancing its endogenous tone through the use of inhibitors of its hydrolytic enzymes, CSPG production by rat and human TGF-β1 stimulated astrocytes was reduced. These effects of 2-AG might reflect its influence on TGF-β1/SMAD pathway, signaling that is involved in CSPG upregulation. The matrix generated from 2-AG-treated astrocytes is less inhibitory to oligodendrocyte differentiation and significantly, 2-AG administration directly promotes the differentiation of rat and human oligodendrocytes cultured under inhibitory conditions. Overall, the data obtained favor targeting the endocannabinoid system to neutralize CSPG accumulation and to enhance oligodendrocyte differentiation., This work was supported by grants to CG from the Ministry of the Economy and Competition (MINECO: SAF2013-42784-R; 16 FELIU ET AL. SAF2016-76449-R) and from the Red Española de Esclerosis Múltiple (REEM) RD16/0015/0021. None of the funding bodies played any role in the study design, data collection, and analysis, the decision to publish, or the preparation of the manuscript. AF is a postdoctoral fellow supported by the MINECO (BES-2014-068459).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Effects of EHP-101 on inflammation and remyelination in murine models of Multiple sclerosis

  • Navarrete, Carmen
  • García-Martín, A
  • Garrido-Rodriguez, Martín
  • Mestre, Leyre
  • Feliú, Ana
  • Guaza, Carmen
  • Calzado, Marco A.
  • Muñoz, Eduardo
Multiple Sclerosis (MS) is characterized by a combination of inflammatory and neurodegenerative processes in the spinal cord and the brain. Natural and synthetic cannabinoids such as VCE-004.8 have been studied in preclinical models of MS and represent promising candidates for drug development. VCE-004.8 is a multitarget synthetic cannabidiol (CBD) derivative acting as a dual Peroxisome proliferator-activated receptor-gamma/ Cannabinoid receptor type 2 (PPAR¿/CB2) ligand agonist that also activates the Hypoxia-inducible factor (HIF) pathway. EHP-101 is an oral lipidic formulation of VCE-004.8 that has shown efficacy in several preclinical models of autoimmune, inflammatory, fibrotic, and neurodegenerative diseases. EHP-101 alleviated clinical symptomatology in EAE and transcriptomic analysis demonstrated that EHP-101 prevented the expression of many inflammatory genes closely associated with MS pathophysiology in the spinal cord. EHP-101 normalized the expression of several genes associated with oligodendrocyte function such as Teneurin 4 (Tenm4) and Gap junction gamma-3 (Gjc3) that were downregulated in EAE. EHP-101 treatment prevented microglia activation and demyelination in both the spinal cord and the brain. Moreover, EAE was associated with a loss in the expression of Oligodendrocyte transcription factor 2 (Olig2) in the corpus callosum, a marker for oligodendrocyte differentiation, which was restored by EHP-101 treatment. In addition, EHP-101 enhanced the expression of glutathione S-transferase pi (GSTpi), a marker for mature oligodendrocytes in the brain. We also found that a diet containing 0.2% cuprizone for six weeks induced a clear loss of myelin in the brain measured by Cryomyelin staining and Myelin basic protein (MBP) expression. Moreover, EHP-101 also prevented cuprizone induced microglial activation, astrogliosis and reduced axonal damage. Our results provide evidence that EHP- 101 showed potent anti-inflammatory activity, prevented demyelination, and enhanced remyelination. Therefore, EHP-101 represents a promising drug candidate for the potential treatment of different forms of MS., This work was supported by grants SAF2017–87701-R (EM), SAF2016–76449-R (GC) from the Ministry of the Economy and Competition (MINECO) co-financed with the European Union FEDER funds. GC was also supported by the Red Española de Esclerosis Múltiple (REEM: RD16/0015/0021) sponsored by the Fondo de Investigación Sanitaria (FIS) (GC). This work was also partially supported by Emerald Health Pharmaceuticals (San Diego, USA).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

How oral probiotics affect the severity of an experimental model of progressive multiple sclerosis? Bringing commensal bacteria into the neurodegenerative process

  • Mestre, Leyre
  • Carrillo-Salinas, F. J.
  • Feliú, Ana
  • Mecha, Miriam
  • Alonso, G.
  • Espejo, Carmen
  • Calvo-Beguería, Laura
  • Luque-García, José Luis
  • Estevez, H.
  • Villar, L.M.
  • Guaza, Carmen
A growing number of studies support that the bidirectional interactions between the gut microbiota, the immune system and the CNS are relevant for the pathophysiology of MS. Several studies have reported alterations in the gut microbiome of MS patients. In addition, a variety of studies in animal models of MS have suggested that specific members of the gut commensal microbiota can exacerbate or ameliorate neuroinflammation. Probiotics represent oral nontoxic immunomodulatory agents that would exert benefits when using in combination with current MS therapy. Here we investigate the effect of Vivomixx on the gut microbiome and central and peripheral immune responses in a murine model of primary progressive MS. Vivomixx administration was associated with increased abundance of many taxa such as Bacteroidetes, Actinobacteria, Tenericutes and TM7. This was accompanied by a clear improvement of the motor disability of Theiler’s virus infected mice; in the CNS Vivomixx reduced microgliosis, astrogliosis and leukocyte infiltration. Notably, the presence of Breg cells (CD19CD5CD1d) in the CNS was enhanced by Vivomixx, and while spinal cord gene expression of IL-1β and IL-6 was diminished, the probiotic promoted IL-10 gene expression. One of the most significant findings was the increased plasma levels of butyrate and acetate levels in TMEV-mice that received Vivomixx. Peripheral immunological changes were subtle but interestingly, the probiotic restricted IL-17 production by Th17-polarized CD4 T-cells purified from the mesenteric lymph nodes of Theiler’s virus infected mice. Our data reinforce the beneficial effects of oral probiotics that would be coadjuvant treatments to current MS therapies., This work was supported by grants from the Ministerio de Economía y Competitividad [MINECO SAF2016-76449-R] and the Red Española de Esclerosis Múltiple [REEM: RD16/0015/0001; RD16/0015/0004; RD16/015/0021], sponsored by the Fondo de Investigación Sanitaria (FIS)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Aging and neuroinflammation: Changes in immune cell responses, axon integrity, and motor function in a viral model of progressive multiple sclerosis

  • Mestre, Leyre
  • Alonso, Graciela
  • Feliú, Ana
  • Mecha, Miriam
  • Martín, C.
  • Villar, Luisa M.
  • Guaza, Carmen
Although aggravated multiple sclerosis (MS) disability has been reported in aged patients, the aging impact on immune cells remodeling within the CNS is not well understood. Here, we investigated the influence of aging on immune cells and the neuroinflammatory and neurodegenerative processes that occur in a well-established viral model of progressive MS. We found an anomalous presence of CD4 T, CD8T, B cells, and cells of myeloid lineage in the CNS of old sham mice whereas a blunted cellular innate and adaptive immune response was observed in Theiler's murine encephalomyelitis virus (TMEV) infected old mice. Microglia and macrophages show opposite CNS viral responses regarding cell counts in the old mice. Furthermore, enhanced expression of Programmed Death-ligand 1 (PD-L1) was found in microglia isolated from old TMEV-infected mice and not in isolated CNS macrophages. Immunocytochemical staining of microglial cells confirms the above differences between young and old mice. Age-related axonal loss integrity in the mouse spinal cord was found in TMEV mice, but a less marked neurodegenerative process was present in old sham mice compared with young sham mice. TMEV and sham old mice also display alterations in innate and adaptive immunity in the spleen compared to the young mice. Our study supports the need of new or adapted pharmacological strategies for MS elderly patients., Red Española de Esclerosis Múltiple, Grant/Award Number: RD 16/0015/0001 and RD16/0015/0021; MINECO, Grant/Award Number: SAF2016- 76449- R; Esclerosis Múltiple España, Grant/Award Number: EMMP2017
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Manipulation of gut microbiota influences immune responses, axon preservation, and motor disability in a model of progressive multiple sclerosis

  • Mestre, Leyre|||0000-0001-6970-2316
  • Carrillo-Salinas, Francisco J.|||0000-0002-7936-5859
  • Mecha, Miriam
  • Feliú, Ana|||0000-0002-1157-1525
  • Espejo, Carmen|||0000-0001-9949-5901
  • Alvarez-Cermeño, José C.|||0000-0002-1345-2837
  • Villar, L. M.
  • Guaza, Carmen|||0000-0003-3240-9807
Gut microbiota dysbiosis has been implicated in MS and other immune diseases, although it remains unclear how manipulating the gut microbiota may affect the disease course. Using a well-established model of progressive MS triggered by intracranial infection with Theiler's murine encephalomyelitis virus (TMEV), we sought to determine whether dysbiosis induced by oral antibiotics (ABX) administered on pre-symptomatic and symptomatic phases of the disease influences its course. We also addressed the effects of microbiota recolonization after ABX withdrawn in the presence or absence of probiotics. Central and peripheral immunity, plasma acetate and butyrate levels, axon damage and motor disability were evaluated. The cocktail of ABX prevented motor dysfunction and limited axon damage in mice, which had fewer CD4 and CD8 T cells in the CNS, while gut microbiota recolonization worsened motor function and axonal integrity. The underlying mechanisms of ABX protective effects seem to involve CD4CD39 T cells and CD5CD1d B cells into the CNS. In addition, microglia adopted a round amoeboid morphology associated to an anti-inflammatory gene profile in the spinal cord of TMEV mice administered ABX. The immune changes in the spleen and mesenteric lymph nodes were modest, yet ABX treatment of mice limited IL-17 production ex vivo. Collectively, our results provide evidence of the functional relevance of gut microbiota manipulation on the neurodegenerative state and disease severity in a model of progressive MS and reinforce the role of gut microbiota as target for MS treatment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

How oral probiotics affect the severity of an experimental model of progressive multiple sclerosis? Bringing commensal bacteria into the neurodegenerative process

  • Mestre, Leyre|||0000-0001-6970-2316
  • Carrillo-Salinas, Francisco J.|||0000-0002-7936-5859
  • Feliú, Ana|||0000-0002-1157-1525
  • Mecha, Miriam
  • Alonso, Graciela
  • Espejo, Carmen|||0000-0001-9949-5901
  • Calvo-Barreiro, Laura|||0000-0002-8524-3305
  • Luque-García, José L.
  • Estevez, Héctor
  • Villar, Luisa M.|||0000-0002-9067-3668
  • Guaza, Carmen|||0000-0003-3240-9807
A growing number of studies support that the bidirectional interactions between the gut microbiota, the immune system and the CNS are relevant for the pathophysiology of MS. Several studies have reported alterations in the gut microbiome of MS patients. In addition, a variety of studies in animal models of MS have suggested that specific members of the gut commensal microbiota can exacerbate or ameliorate neuroinflammation. Probiotics represent oral nontoxic immunomodulatory agents that would exert benefits when using in combination with current MS therapy. Here we investigate the effect of Vivomixx on the gut microbiome and central and peripheral immune responses in a murine model of primary progressive MS. Vivomixx administration was associated with increased abundance of many taxa such as Bacteroidetes, Actinobacteria, Tenericutes and TM7. This was accompanied by a clear improvement of the motor disability of Theiler's virus infected mice; in the CNS Vivomixx reduced microgliosis, astrogliosis and leukocyte infiltration. Notably, the presence of Breg cells (CD19 + CD5 + CD1d high) in the CNS was enhanced by Vivomixx, and while spinal cord gene expression of IL-1β and IL-6 was diminished, the probiotic promoted IL-10 gene expression. One of the most significant findings was the increased plasma levels of butyrate and acetate levels in TMEV-mice that received Vivomixx. Peripheral immunological changes were subtle but interestingly, the probiotic restricted IL-17 production by Th17-polarized CD4 + T-cells purified from the mesenteric lymph nodes of Theiler's virus infected mice. Our data reinforce the beneficial effects of oral probiotics that would be coadjuvant treatments to current MS therapies.